No Data
Hong Kong stocks unusual movement | Boran Biotechnology (06955) rose nearly 9%, the initial manifestation of the company's scale effect, with a continuous accumulation and volume increase of similar biopharmaceutical products listed.
Boan Biological (06955) rose nearly 9%, as of the time of publication, up 8.92% to 8.3 Hong Kong dollars, with a turnover of 15.9053 million Hong Kong dollars.
[Brokerage Focus] zhongtai Securities first initiated a "shareholding" rating on Boan Biology (06955), indicating that the progress of listing varieties is leading among similar products.
Kingwu Financial News | Zhongtai Securities issued a research report, stating that Boan Biotechnology (06955) continuously accumulates and expands its listed biosimilar varieties, with revenues reaching 0.16, 0.52, and 0.62 billion yuan in 2021/2022/2023, respectively. In the first half of 2024, revenue reached 0.36 billion yuan, showing initial effects of economies of scale. Sales expense ratio, management expense ratio, and research and development expense ratio (R&D spending in 2024H1 decreased by about 40.2 million yuan, mainly due to increased R&D investment in deferred development costs in the second half of 2023, and more R&D projects progressing to Phase III clinical trials being capitalized as a result.
Boan Biotechnology (06955.HK): Innovative combination of imitation and creation with emerging macromolecules, rapid improvement in profitability + innovative strength.
Backed by luye pharma, the company develops research, production, and sales in parallel. The company has excellent capabilities in the research, production, and commercialization of large molecules (including biosimilars, innovative antibodies, ADCs, etc.), with a wide layout in multiple therapeutic areas. The listed company is luye pharma group.
BOAN BIOTECH: INTERIM REPORT 2024
Shandong Boan Biotechnology Swings to Profit in H1
《Performance》 Boan Biological (06955.HK) reported a net profit of 61.67 million RMB for the first half, turning from loss to profit.
Boan Biotechnology (06955.HK) has announced its interim performance for the six months ending in June, with revenue of 0.363 billion RMB, an increase of 38.9% year-on-year. It recorded a net profit of 61.67 million yuan, compared to a loss of 0.12 billion yuan in the same period last year, turning losses into profits; earnings per share were 12 cents. No interim dividend will be paid.
No Data
No Data